July 2021 PMID 33878338

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.

David C Wheeler, Robert D Toto, Bergur V Stefánsson, Niels Jongs, Glenn M Chertow, Tom Greene, Fan Fan Hou, John J V McMurray, Roberto Pecoits-Filho, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Kausik Umanath, Anna Maria Langkilde, Hiddo J L Heerspink

Full text PDF Download social card

Mentions

224

Peak: 78 in Jan 2023

across 5 sources since Apr 2021

Extended reach

440,406

potential audience

Total likes

271

Video views

4,703

Mentions per month

Apr 2021 – Aug 2024

Where it's discussed

X / Twitter200 posts
News15 articles
Facebook4 posts
Blogs3 articles
YouTube2 videos

AI synopsis

What people are saying

The discussions around the article emphasize the promising results of dapagliflozin in reducing major kidney events in IgA nephropathy patients. For instance, phrases like 'the effect beneficial' and 'significantly lower eGFR decline' reflect a sense of optimism regarding these findings. The tone, predominantly positive, suggests that many participants view these results as groundbreaking, which contributes to the overall perception of the publication's significant impact.

AgreementModerate agreement

Many posts are supportive of the findings, highlighting the efficacy of dapagliflozin for IgA nephropathy.

InterestHigh interest

The discussions indicate a strong interest in treatment advancements, as evidenced by several posts sharing summaries and links to the study.

EngagementModerate engagement

While some posts delve into specifics like eGFR changes and clinical implications, most remain at a surface level.

ImpactHigh impact

Users believe the findings of the study could significantly influence treatment options and patient outcomes.

Abstract in brief

The DAPA-CKD trial showed that dapagliflozin significantly lowers the risk of major kidney problems in patients with IgA nephropathy, a common kidney condition.
In the study, participants taking dapagliflozin experienced a lower rate of kidney function decline and fewer adverse events over a median follow-up of 2.1 years compared to those on a placebo.
Dapagliflozin also led to a 26% reduction in urinary albumin-to-creatinine ratio, indicating improved kidney health, without any new safety issues.

Read the full abstract

All mentions

Innovative Treatments for IgA Nephropathy Explained

In this video, Prof. Dr. Jürgen Floege discusses established and innovative therapies for IgA nephropathy. Recent clinical trials reveal promising results for treatments like methylprednisolone, showing significant…

MARKUS at HOMe · Feb 16, 2024 4,121 views

Impact of Dapagliflozin on Kidney Health in IgA Nephropathy

In this academic review, Professor Matthias Girndt presents key studies from 2021, focusing on significant findings from the DAPA-CKD trial. The trial demonstrated that dapagliflozin effectively reduces kidney…

MARKUS at HOMe · Dec 23, 2021 582 views

Ian McCoy, MD, MS

@NephroNinja · X

@sonia_rgzr This slide seems intentionally misleading. DAPA reduced the primary outcome in the IgAN subset (HR 0.29; 95% CI 0.12-0.73) and still decreased the rate of decline in eGFR (significantly after the initial eGFR drop in the first two weeks). https://t.co/AyD4Nc3C85

Aug 6, 2024 · 1 like · 1 share · 834 followers View post →

kintya

@kintya2 · X

https://t.co/YgULrB2BYe DAPA-CKDのサブ解析のIgA腎症 SGLT2阻害薬 vs placebo eGFR変化 -3.5 vs -4.7 sparsentanはSGLT2阻害薬と同程度(eGFR変化の差 1ml/年)の効果がある。

Dec 15, 2023 · 314 followers View post →

Swasti Chaturvedi

@SwastiThinks · X

But what about #SGLT2Inhibitors a.k.a #FLOZINS? Well #DAPA-CKD study looked into participants with #IgAN. Here are few summary slides and the link to the study https://t.co/PG1bywk1NL https://t.co/lAfa3Ur9Qi

Nov 22, 2023 · 1 like · 1,853 followers View post →

Todd C. Lee

@DrToddLee · X

@kaulcsmc @brendonneuen @BradRovin @hswapnil https://t.co/a9c3k1QpYK

Nov 3, 2023 · 14,910 followers View post →

@CKD_ce

@ckd_ce · X

54) In a pre-specified analysis of the #DAPA_CKD trial, particularly in participants with #IgAN, dapagliflozin was shown to reduce the risk of CKD progression with a favorable safety profile #Nephpearls https://t.co/44VCWihHCw https://t.co/LgK7a0Km4D

Oct 11, 2023 · 3 likes · 2,636 followers View post →

Shubham Kumar

@einsteinkid_007 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Aug 18, 2023 · 20 shares · 73 followers View post →

Nader

@Nader62321135 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Aug 17, 2023 · 5 shares · 85 followers View post →

Nader

@Nader62321135 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Aug 17, 2023 · 20 shares · 85 followers View post →

CJ Stefanidis

@cjstefanidis · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 23, 2023 · 14 shares · 534 followers View post →

Ahmed Serageldeen

@ahmed_shaban_s · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 22, 2023 · 14 shares · 223 followers View post →

melvy june

@melvyjune · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 18, 2023 · 14 shares · 59 followers View post →

Mihir Kumar Jha

@diwtarni · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 15, 2023 · 14 shares · 180 followers View post →

Loma Linda Nephrology

@LLNeph · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 15, 2023 · 14 shares · 680 followers View post →

Sayna Norouzi, MD, FASN

@SaynaNorouzi · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 15, 2023 · 14 shares · 5,919 followers View post →

aiaiaichin

@aiaiaichin1 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 14, 2023 · 14 shares · 281 followers View post →

najiba world

@WafaaArache · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 14, 2023 · 14 shares · 755 followers View post →

Carmela Ramos

@Carmen98607067 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 14, 2023 · 14 shares · 4 followers View post →

Joel CM. MD

@joeMD77 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 14, 2023 · 14 shares · 1,424 followers View post →

PH.B.A.Y.B

@AdeenPh · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 14, 2023 · 14 shares · 793 followers View post →

Lakshya kapoor

@kapoorl1997 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 14, 2023 · 14 shares · 29 followers View post →

Dr. Raúl Zenteno Langle

@DrZentenoLangle · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KID…

Apr 14, 2023 · 14 shares · 389 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Use of SGLT2 inhibitors in IgA Nephropathy (IgAN) #NKFClinicals #Nephpearls DAPA-CKD https://t.co/yW7aEcuOMo EMPA-KIDNEY https://t.co/7PIWHc8Ame https://t.co/cjUES79CV7

Apr 14, 2023 · 51 likes · 14 shares · 33,568 followers View post →

Ryu

@Ryu04196650Ryu · X

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy 2021 @Kidney_Int DAPA-CKDのsub group解析 IgA患者群においても腎予後改善、アルブミン尿の減少 https://t.co/Jp2p0Gkmtx

Mar 30, 2023 · 1 like · 4,799 followers View post →

INForm Nephro

@InformNephro · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 23, 2023 · 20 shares · 803 followers View post →

Kidney Transplant Update 2024

@KTUpdate2024 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 23, 2023 · 20 shares · 203 followers View post →

Siddhavinayak Rajmane

@SiddhvinayakR · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 19, 2023 · 20 shares · 398 followers View post →

Dr. Ali Alshahrani

@AliShahrani04 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 17, 2023 · 24 shares · 36 followers View post →

The Cardiometabolic Forum

@theCMforum · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 16, 2023 · 24 shares · 257 followers View post →

Tired & Sakit

@tulunsokit · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 15, 2023 · 20 shares · 3,727 followers View post →

Swasti Chaturvedi

@SwastiThinks · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 15, 2023 · 20 shares · 1,853 followers View post →

Jyoti Aggarwal

@Agarwalja_Aiims · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 14, 2023 · 20 shares · 338 followers View post →

Kevin

@Kevinlyttle1 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 14, 2023 · 52 shares · 36 followers View post →

Kajaree Giri

@KajareeG · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 13, 2023 · 20 shares · 1,114 followers View post →

Kajaree Giri

@KajareeG · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 13, 2023 · 24 shares · 1,114 followers View post →

Dr Maryam مريم Paz

@DrMaryamPaz · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 13, 2023 · 52 shares · 742 followers View post →

DocRaissa

@MomZillaMD · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 12, 2023 · 52 shares · 112 followers View post →

Anupama Y J

@anupamayj · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 12, 2023 · 52 shares · 956 followers View post →

AATIF Taoufiq

@TaoufiqAatif · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 12, 2023 · 24 shares · 9 followers View post →

Jeyakumar Meyyappan

@meyyappannephro · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 12, 2023 · 52 shares · 1,042 followers View post →

Garima Aggarwal

@gag_aggarwal · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 12, 2023 · 52 shares · 3,357 followers View post →

LuisNuñez

@LuisNue88367349 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 12, 2023 · 52 shares · 162 followers View post →

José Cabrales, MD, FASN

@josecabrales11 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 12, 2023 · 52 shares · 314 followers View post →

micromima63

@micromima633 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 12, 2023 · 52 shares · 29 followers View post →

Sruthi Haridas

@sruthiharidas_ · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 454 followers View post →

fabiola

@drapazos · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 44 followers View post →

닥터언니

@anyonyingpui · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 282 followers View post →

Jinwook Park

@pjinw46 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 20 shares · 310 followers View post →

S.Runprapan

@wwanderlusterr · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 48 followers View post →

Lakshna Sankar

@LakshnaSankar · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 147 followers View post →

Dra. Erica Yama

@Ericayamitayama · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 96 followers View post →

Deb Choudhury

@DocereDeb · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 121 followers View post →

Preda Cristina Evelina

@EvelinaPreda · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares View post →

Thongxay C.,MD

@no_cvs · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 75 followers View post →

Roberto Gutiérrez

@DrRobertoGuti · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 781 followers View post →

Pharma World Today

@pharmaworld2day · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 5 shares · 171 followers View post →

Nader

@Nader62321135 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 85 followers View post →

Thahir

@docthahir · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 753 followers View post →

Benito Valdepenas

@Benitocept · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 547 followers View post →

Samuel García Rubio

@SonoSamMD · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 1,277 followers View post →

najiba world

@WafaaArache · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 755 followers View post →

Iqraa Kidney Care

@iqraakidneycare · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 539 followers View post →

Arun Rajasekaran, MD, FACP, FASN, FNKF

@Nephronpower · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 1,417 followers View post →

Swetha Kanduri

@SwethaKanduriMD · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 20 shares · 1,665 followers View post →

Sandra Chase

@SandraC75363814 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 24 followers View post →

Anthony Chan Yon Quan

@anthonychanmd · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 35 followers View post →

Anthony Chan Yon Quan

@anthonychanmd · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 35 followers View post →

aiaiaichin

@aiaiaichin1 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 281 followers View post →

Oscar

@OscarAlfredoLu4 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 192 followers View post →

Diego

@argudosanchezdi · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 430 followers View post →

Kenar Jhaveri

@kdjhaveri · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 20 shares · 11,672 followers View post →

kopilady

@kopilady86 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 3 followers View post →

Iqraa Kidney Care

@iqraakidneycare · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 539 followers View post →

Luz Marina Mejia

@LuzMarMejia · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 402 followers View post →

kopilady

@kopilady86 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 3 followers View post →

Rosina Dal Maso

@MasoRosina · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 57 followers View post →

Dr Salah

@DrSalah_nephro · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 297 followers View post →

CY Teh

@CheeYongTeh1 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 8 followers View post →

SABARINATH S MD,DM,PDF(Renal Tx),FASN,FISN

@sabarivenus · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 1,003 followers View post →

Guadalupe Hernandez

@mghbrr · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 216 followers View post →

SABARINATH S MD,DM,PDF(Renal Tx),FASN,FISN

@sabarivenus · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 20 shares · 1,003 followers View post →

Navinath M

@navinath_m · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 239 followers View post →

Solivagant

@eesanisai · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 20 shares · 19 followers View post →

DaniReuma

@dani_reuma · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 11, 2023 · 24 shares · 362 followers View post →

Dr Jimmy

@drjimmy1123 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 31 followers View post →

MªAngeles Fenollosa

@mafenollosa · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 348 followers View post →

Vincent Anthony Tang

@VASTangMD · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 1,224 followers View post →

Jose De La Flor

@josedelaflor4 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 457 followers View post →

Arshad Ali

@aldorenin · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 11, 2023 · 52 shares · 594 followers View post →

Fadel Alrowaie

@fadelrowaie · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 10, 2023 · 24 shares · 25,016 followers View post →

Fayyaan Badhaadhina

@FayyaanB · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 10, 2023 · 52 shares · 9 followers View post →

Johann Morelle

@JohannMorelle · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 10, 2023 · 5 shares · 671 followers View post →

Johann Morelle

@JohannMorelle · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 10, 2023 · 20 shares · 671 followers View post →

Abhishek

@aksrulz13 · X

RT @edgarvlermamd: Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t…

Jan 10, 2023 · 24 shares · 621 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t.co/AUhn7VXl4s https://t.co/zeO7bzk3Yc

Jan 10, 2023 · 8 likes · 5 shares · 33,568 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

Use of SGLT2 inhibitors in IgA Nephropathy #NephJC #Nephpearls DAPA-CKD https://t.co/nqIsyBRioU EMPA-KIDNEY https://t.co/AUhn7VXl4s https://t.co/31hRD1YfUv

Jan 10, 2023 · 62 likes · 24 shares · 33,568 followers View post →

Dr Chan Chee Eng

@ChanCheeEng2 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 10, 2023 · 52 shares · 87 followers View post →

Shubharthi Kar, MD, FISN

@shubharthikar · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 10, 2023 · 52 shares · 2,950 followers View post →

Shweta Shah M.D; FASN

@nefron1310 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 10, 2023 · 52 shares · 1,454 followers View post →

Dr. Divya Bajpai

@divyaa24 · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 10, 2023 · 20 shares · 9,210 followers View post →

Tired & Sakit

@tulunsokit · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 10, 2023 · 52 shares · 3,727 followers View post →

Nephrology Journal Club

@NephJC · X

RT @edgarvlermamd: IgA Nephropathy Landmark Trials #Nephpearls #NephJC Table by @divyaa24 #VisualAbstract @KidneyBea_n @kidney_boy STOP…

Jan 10, 2023 · 20 shares · 38,257 followers View post →

Jathzibe Rosas

@jathzi · X

RT @ralcazara: #reunionSOMANE - Eduardo Gutierrez nos analiza el ensayo DAPA-CKD. En la NIgA el efecto beneficioso de los iSGLT2 es claro…

Jun 18, 2022 · 6 shares · 75 followers View post →

Cristina Galeano Álvarez

@Cr_Galeano · X

RT @ralcazara: #reunionSOMANE - Eduardo Gutierrez nos analiza el ensayo DAPA-CKD. En la NIgA el efecto beneficioso de los iSGLT2 es claro…

Jun 17, 2022 · 6 shares · 370 followers View post →

Faby G.

@Fabiolaghh · X

RT @ralcazara: #reunionSOMANE - Eduardo Gutierrez nos analiza el ensayo DAPA-CKD. En la NIgA el efecto beneficioso de los iSGLT2 es claro…

Jun 17, 2022 · 6 shares · 410 followers View post →

Anace Pastor ✨️ Renalis

@anace710 · X

RT @ralcazara: #reunionSOMANE - Eduardo Gutierrez nos analiza el ensayo DAPA-CKD. En la NIgA el efecto beneficioso de los iSGLT2 es claro…

Jun 17, 2022 · 6 shares · 1,899 followers View post →

Roberto Gutiérrez

@DrRobertoGuti · X

RT @ralcazara: #reunionSOMANE - Eduardo Gutierrez nos analiza el ensayo DAPA-CKD. En la NIgA el efecto beneficioso de los iSGLT2 es claro…

Jun 17, 2022 · 6 shares · 781 followers View post →

Sociedad Madrileña de Nefrología (SOMANE)

@SOMANEorg · X

RT @ralcazara: #reunionSOMANE - Eduardo Gutierrez nos analiza el ensayo DAPA-CKD. En la NIgA el efecto beneficioso de los iSGLT2 es claro…

Jun 17, 2022 · 6 shares · 3,571 followers View post →

Roberto Alcazar

@ralcazara · X

Jun 17, 2022 · 13 likes · 6 shares · 3,901 followers View post →

Miguel Guillen 140#

@AnayaGuillen · X

#IgANDay an #proteinuria: SGLT2 new hope ? (1/3) : K Int . 2021 Jul;100(1):215-224.doi: 10.1016/j.kint.2021.03.033.2021 Apr 18. A prespecified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

May 14, 2022 · 421 followers View post →

Shivam Joshi, MD

@sjoshimd · X

Yet a third mind-blowing paper (late in posting, as usual): A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy https://t.co/wD4zte3FWW https://t.co/cIgrTwGmea

Feb 27, 2022 · 4 likes · 3,773 followers View post →

Dexmedetomidina

@hexolum_fakir · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Dec 9, 2021 · 87 shares · 513 followers View post →

長澤　将（腎臓内科医）

@RealTNagasawa · X

Nov 6, 2021 · 37 likes · 1 share · 5,208 followers View post →

令和姥捨山病院窓際内科

@setrq9HfAVRwdju · X

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney ev… https://t.co/mpcpNBvLpn

Oct 17, 2021 · 782 followers View post →

くりにかる3A5＠Ph.D.

@clinical89314 · X

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy https://t.co/14lNND9eAt

Sep 11, 2021 · 1 like · 1,284 followers View post →

Sian Griffin

@toomuchaltitude · X

RT @ISNkidneycare:

Jul 30, 2021 · 2 shares · 972 followers View post →

Charu Malik

@CharuMalik_ISN · X

RT @ISNkidneycare:

Jul 30, 2021 · 2 shares · 1,167 followers View post →

Int Society of Nephrology

@ISNkidneycare · X

Jul 30, 2021 · 11 likes · 2 shares · 29,174 followers View post →

Lewis

@lewitmann · X

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy - PubMed https://t.co/4XrLRBkrML

Jul 12, 2021 · 93 followers View post →

Rob Bruno

@drrobbruno · X

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy - Kidney International https://t.co/B5JQ0Z1s9N

Jul 3, 2021 · 1 like · 74 followers View post →

MªAngeles Fenollosa

@mafenollosa · X

RT @ISNkidneycare: ➡️ A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney even…

Jun 22, 2021 · 7 shares · 348 followers View post →

Gerardo Alfaro

@gerardoalfaromd · X

RT @ISNkidneycare: ➡️ A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney even…

Jun 22, 2021 · 7 shares · 341 followers View post →

Charu Malik

@CharuMalik_ISN · X

RT @ISNkidneycare: ➡️ A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney even…

Jun 22, 2021 · 7 shares · 1,167 followers View post →

Gonzalo Bautista Prieto. MD

@GonzalBautistaP · X

RT @ISNkidneycare: ➡️ A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney even…

Jun 21, 2021 · 7 shares · 828 followers View post →

lamarche caroline

@lamarchecaroli1 · X

RT @ISNkidneycare: ➡️ A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney even…

Jun 21, 2021 · 7 shares · 76 followers View post →

Caitlyn Vlasschaert

@DrFlashHeart · X

RT @ISNkidneycare: ➡️ A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney even…

Jun 21, 2021 · 7 shares · 3,266 followers View post →

Bacary Ba

@bacary_ba · X

RT @ISNkidneycare: ➡️ A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney even…

Jun 21, 2021 · 7 shares · 1,058 followers View post →

Int Society of Nephrology

@ISNkidneycare · X

Jun 21, 2021 · 14 likes · 7 shares · 29,174 followers View post →

Joseph Vassalotti, MD

@Joe_Vassalotti · X

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy https://t.co/sxy4HESak1 https://t.co/1cBdMatTET

May 19, 2021 · 2 likes · 2,070 followers View post →

UCL Discovery

@ucl_discovery · X

Open Access UCL Research: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy https://t.co/8oKObXcp42

May 10, 2021 · 2,524 followers View post →

El Residente Chapín

@residentechapin · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 28, 2021 · 87 shares · 109 followers View post →

Celinuchis36

@celinuchis36 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 25, 2021 · 87 shares · 42 followers View post →

Dhylan Soliz

@dhylan2208 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 22, 2021 · 87 shares · 193 followers View post →

Javi Juega

@JJuega · X

RT @beaff26: Waiting for the miracle to come... A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapaglifl…

Apr 22, 2021 · 2 shares · 351 followers View post →

Juan Carlos Obaya

@jcobaya69 · X

RT @beaff26: Waiting for the miracle to come... A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapaglifl…

Apr 22, 2021 · 2 shares · 857 followers View post →

Beatriz Fernandez Fernandez

@beaff26 · X

Waiting for the miracle to come... A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. - Kidney International https://t.co/3gUjefnUWH

Apr 21, 2021 · 7 likes · 2 shares · 2,300 followers View post →

Laura_Medina

@LauraMe09907169 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 21, 2021 · 87 shares · 112 followers View post →

ThunderFlash

@JavOc3 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 20, 2021 · 87 shares · 125 followers View post →

Carlos Santos Alonso

@CSantsal · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 19, 2021 · 87 shares · 75 followers View post →

✨

@DraPettite · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 19, 2021 · 87 shares · 1,408 followers View post →

sara

@sr_gds · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 19, 2021 · 87 shares · 34 followers View post →

Roberto Gutiérrez

@DrRobertoGuti · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 19, 2021 · 87 shares · 781 followers View post →

MªAngeles Fenollosa

@mafenollosa · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 19, 2021 · 87 shares · 348 followers View post →

Diana Morales

@DianaMg26 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 109 followers View post →

Hermann Hernández MD.

@HERMANNHV · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 210 followers View post →

Adrián RH

@_telurio · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 54 followers View post →

Dra.Bianka Carolina S Peralta.

@draperalta24 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 187 followers View post →

Tudoc_toronline®️

@TToronline · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 6 followers View post →

Raul Villar

@DrRaulvillar · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 410 followers View post →

katiuska Ivanovak

@doctita · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 993 followers View post →

charmedbross

@charmedbross · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 92 followers View post →

Juan Manuel Núñez

@Juanma_JMNC · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 91 followers View post →

Eduardo Ortiz MD

@Lalortiz_MD · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 98 followers View post →

Miguel Cedeño Moreno

@miguecedeno · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 303 followers View post →

Sofia San Roman

@SanSofisan · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 153 followers View post →

adelaida morales

@MoralesAdelaida · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 68 followers View post →

Doris Lopez

@dorisalopez · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 138 followers View post →

ANTONIO JIMENEZ

@Ajim22ANTONIO · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 145 followers View post →

Manuel Vazquez V

@ManuelVVidaurre · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 277 followers View post →

Ricardo Silvariño

@rsilvarino · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 4,125 followers View post →

manuel macia heras

@mmacia25 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 808 followers View post →

Palalo di Osbourne

@paux99 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 568 followers View post →

Luis Godínez

@luisgod91 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 189 followers View post →

Juan Maza

@OldmanYoung616 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 83 followers View post →

Marisol

@Mary880307 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 435 followers View post →

Diana Dehesa

@dehesa_diana · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 18, 2021 · 87 shares · 1,689 followers View post →

Guillermo Navarro Blackaller

@NefroBlackaller · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 340 followers View post →

Benito Navarrete

@BenNavarrete · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 604 followers View post →

Norma Guerra

@nelizguerra6 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 397 followers View post →

Raul Fonseca

@Rulex74c · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 511 followers View post →

Julian mauricio Baez

@jbaez311 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 28 followers View post →

Carlos Alvarez

@CarlosAlvarezDM · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 662 followers View post →

patricia smith

@patinolan · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 89 followers View post →

Dr. Ronald Caraballo NEFROLOGO

@ronald_nefro · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 661 followers View post →

Nunca dejar que otros paguen por tus errores

@MonaresTI · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 7,273 followers View post →

Shirley Pineda

@Pineda_shir · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 901 followers View post →

Carlos Daniel Jiménez

@CarlosDrjimenez · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 330 followers View post →

Dr. Carlos Orellana

@orellanamd · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 551 followers View post →

Jared siñani

@JaredSinani · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 10 followers View post →

Javier Honorio

@Javierhv_17 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 144 followers View post →

Pablo

@pabloruanos · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 1,122 followers View post →

Auténticamente Yo

@healthand_skin · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 170 followers View post →

Ricardo Steveen Guerrero Zambrano

@ricardosgz22 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 58 followers View post →

Henry Gaviria

@henrygav5 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 256 followers View post →

Héctor Rojas Glz

@RgGlz · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 81 followers View post →

fausto heredia z.

@drfherediaz · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 4,353 followers View post →

Pablo Angeles Tacchino

@pabloange · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 751 followers View post →

Marco Anaya_NefroX

@Nefrotweet · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 1,746 followers View post →

José Mª Gª Quintana

@jose_g_quintana · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 841 followers View post →

FERCHO

@FerchoR18 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 129 followers View post →

Dra. Dahiana Pepén Morales

@dra_pepen · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 174 followers View post →

Angela Córdoba Hurtado

@AngelaCordobaH · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 529 followers View post →

J.M. Vera Zertuche

@VeraZertucheMD · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 11,706 followers View post →

Irene Mínguez Toral

@irenosian · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 483 followers View post →

Victor Vera

@victorvf87 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 197 followers View post →

Francisco Torres Pérez

@Francis29265937 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 302 followers View post →

DaniReuma

@dani_reuma · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 362 followers View post →

Jose De La Flor

@josedelaflor4 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 457 followers View post →

Dra. Migdalia Martínez

@nefroproteccion · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 15 followers View post →

Alfa

@AlfasaurioAlfa · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 327 followers View post →

Oscar Contreras

@ooscar_88 · X

RT @JonathanNefro: En NEFROPATÍA por IgA, DAPAGLIFLOZIN se asoció a reducir 71% en evento compuesto cardiovascular/renal y 71% el específic…

Apr 17, 2021 · 87 shares · 1,461 followers View post →

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Innovative Treatments for IgA Nephropathy Explained

Impact of Dapagliflozin on Kidney Health in IgA Nephropathy